Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Vaxart, Inc. (NASDAQ:VXRT) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.73 and traded as low as $0.72. Vaxart shares last traded at $0.74, with a volume of 1,361,347 shares.

Vaxart Stock Down 0.2 %

The firm has a market cap of $168.34 million, a PE ratio of -1.80 and a beta of 0.62. The stock has a 50 day moving average price of $0.66 and a two-hundred day moving average price of $0.73.

Institutional Trading of Vaxart

Large investors have recently bought and sold shares of the stock. Mesirow Financial Investment Management Inc. raised its holdings in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares during the last quarter. XTX Topco Ltd increased its position in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 122,387 shares during the period. Geode Capital Management LLC raised its stake in Vaxart by 15.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after acquiring an additional 2,095,274 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.